CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0683 (clinicaltrials.gov NCT No: NCT01186991)
Title:A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF ONARTUZUMAB AND/OR BEVACIZUMAB IN COMBINATION WITH PACLITAXEL IN PATIENTS WITH METASTATIC, TRIPLE-NEGATIVE BREAST CANCER
Principal Investigator:Vicente Valero
Treatment Agent:Bevacizumab; MetMAb/Placebo; Paclitaxel
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if onartuzumab and/or
bevacizumab given in combination with paclitaxel can help to control
triple-negative breast cancer that has spread. The safety of these drug
combinations will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Breast
Phase of Study:Phase II
Treatment Agents:Bevacizumab
MetMAb/Placebo
Paclitaxel
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Genentech
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Vicente Valero
Dept:Breast Medical Oncology
For Clinical Trial Enrollment:713-792-2817
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults